Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Corrigendum to "HIV-associated lymphoma" [Best Pract Res Clin Haematol 25 (2012) 101-117].

Best practice & research. Clinical haematology·2024
Same author

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.

Blood advances·2022
Same author

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.

Journal of the National Comprehensive Cancer Network : JNCCN·2022
Same author

Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma.

Journal of geriatric oncology·2022
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: May 24, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

HIV-associated lymphoma.

Lawrence D Kaplan1

  • 1Adult Lymphoma Program, University of California, San Francisco, CA 94143, USA. lkaplan@medicine.ucsf.edu

Best Practice & Research. Clinical Haematology
|March 14, 2012
PubMed
Summary
This summary is machine-generated.

Patients with HIV-associated lymphoma can receive standard chemotherapy with good outcomes. Combination antiretroviral therapy (cART) improves prognosis, but requires careful monitoring for drug interactions between HIV and chemotherapy treatments.

More Related Videos

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

Related Experiment Videos

Last Updated: May 24, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

Area of Science:

  • Oncology
  • Infectious Diseases
  • Hematology

Background:

  • The incidence of aggressive lymphoma is notably higher in individuals with Human Immunodeficiency Virus (HIV) infection compared to the general population.
  • Combination antiretroviral therapy (cART) has led to a decrease in lymphoma incidence and improved outcomes for HIV-infected patients undergoing chemotherapy.

Purpose of the Study:

  • To review the current understanding of HIV-associated lymphoma treatment.
  • To highlight the efficacy of standard chemotherapy regimens and the importance of managing unique risks in this patient population.

Main Methods:

  • Review of current literature on HIV-associated lymphoma.
  • Analysis of treatment outcomes with standard immuno-chemotherapy regimens.
  • Discussion of potential drug interactions and management strategies.

Main Results:

  • Standard immuno-chemotherapy regimens, including infusional EPOCH-R, are effective for HIV-associated lymphoma.
  • High-dose chemotherapy with autologous stem cell support is a well-tolerated and effective option for relapsed cases.
  • Opportunistic infections are less common causes of death, but drug interactions pose unique risks.

Conclusions:

  • HIV-associated lymphoma patients can generally be treated with the same regimens as immunocompetent individuals, with similar positive outcomes.
  • Close communication between oncologists and HIV providers is crucial to manage potential interactions between cART and chemotherapy.
  • Careful management of drug interactions is essential for optimizing treatment efficacy and patient safety.